Abstract:Purpose: The GX1 peptide (CGNSNPKSC) can specifically bind to TGM2 and possesses the ability to target the blood vessels of gastric cancer. This study intends to develop an integrated dual-functional probe with higher affinity, specificity and targeting and to characterize it in vivo and in vitro. Methods: The dimer and tetramer of GX1 were prepared using cross-linked PEG and labeled with Tc-99m. The best targeting probe [PEG-(GX1)(2)] was selected by gamma camera imaging in nude mouse models of gastric cancer. Re-188-PEG-(GX1)(2) was prepared and characterized through cell binding analysis and competitive inhibition experiments, gamma camera imaging, MTT analysis and flow cytometry, BLI, immunohistochemistry, HE staining and biochemical analysis. Results: PEG-(GX1)(2) bound specifically to Co-HUVEC with higher affinity than GX1. Re-188-PEG-(GX1)(2) had better ability to target gastric cancer in tumor-bearing nude mice and higher T/H ratios than Re-188-GX1. (188)RePEG-(GX1) 2 inhibited the growth of Co-HUVEC and induced apoptosis, and its effects were more robust than those of Re-188-GX1. BLI showed that (188R)e-PEG-(GX1) 2 inhibited tumor proliferation in vivo with a stronger effect than Re-188-GX1. Compared with Re-188-GX1, Re-188-PEG-(GX1) 2 suppressed tumor angiogenesis and tumor cell proliferation and induced tumor cell apoptosis in vivo. The Re-188-PEG-(GX1) 2 group did not cause visible changes in liver and kidney morphology and function in vivo. Conclusion: The dimer of GX1 was synthesized by using cross-linked PEG, and then Re-188-PEG-(GX1) 2 was prepared. This radiopharmaceutical played both diagnostic and therapeutic functions, and gamma camera imaging could be utilized to detect the distribution of drugs in vivo during treatment. Through a series of experiments in vitro and in vivo, the feasibility of the drug was confirmed, and these results laid the foundation for the subsequent development and application of GX1.

In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

Quantitatively Visualizing Tumor-Related Protease Activity in Vivo Using a Ratiometric Photoacoustic Probe.

In Vivo Mapping And Assay Of Matrix Metalloproteases For Liver Tumor Diagnosis

Simultaneous Monitoring of Multi-Enzyme Activity and Concentration in Tumor Using a Triply Labeled Fluorescent In Vivo Imaging Probe.

Molecular Imaging of Proteases in Cancer.

Molecular Imaging Of Proteases In Cancer

Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent.

In Situ Protease Secretion Visualization and Metastatic Lymph Nodes Imaging Via a Cell Membrane-Anchored Upconversion Nanoprobe.

MMP-2-responsive fluorescent nanoprobes for enhanced selectivity of tumor cell uptake and imaging

A dual-protease-triggered chemiluminescent probe for precise tumor imaging

Ratiometric Imaging Of Mmp-2 Activity Facilitates Tumor Detection Using Activatable Near-Infrared Fluorescent Semiconducting Polymer Nanoparticles

Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)

Imaging application of an MMP2-sensitive tumor-targeted prussian blue fluorescent nanoprobe

Correction to “novel 19F Activatable Probe for the Detection of Matrix Metalloprotease-2 Activity by MRI/MRS”

A DNA-directed covalent conjugation fluorescence probe for in vitro detection of functional matrix metalloproteinases.

In Vivo Visualization Of Gamma-Glutamyl Transpeptidase Activity With An Activatable Self-Immobilizing Near-Infrared Probe

In Situ Ratiometric SERS Imaging of Intracellular Protease Activity for Subtype Discrimination of Human Breast Cancer.

Optical imaging of MMP-12 active form in inflammation and aneurysm

In Vitro Testing of a Protease-Sensitive Contrast Agent for Optoacoustic Imaging.

Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe